New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoclopramide hydrochloride monohydrate 5 mg/ml;   - solution for injection - 5 mg/ml - active: metoclopramide hydrochloride monohydrate 5 mg/ml   excipient: hydrochloric acid sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoclopramide hydrochloride monohydrate 5 mg/ml;   - solution for injection - 5 mg/ml - active: metoclopramide hydrochloride monohydrate 5 mg/ml   excipient: hydrochloric acid sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - metoclopramide hydrochloride monohydrate 5 mg/ml - solution for injection - 5 mg/ml - active: metoclopramide hydrochloride monohydrate 5 mg/ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva santé animale sa-nv - metoclopramide hydrochloride 5 mg/ml - eq. metoclopramide 4,457 mg/ml - solution for injection - 5 mg/ml - metoclopramide hydrochloride 5 mg/ml - metoclopramide - dog; cat

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

le vet. (beheer) b.v. - metoclopramide hydrochloride 5 mg/ml - eq. metoclopramide 4,457 mg/ml - solution for injection - 5 mg/ml - metoclopramide hydrochloride 5 mg/ml - metoclopramide - dog; cat

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dechra regulatory b.v. - metoclopramide hydrochloride 5 mg/ml - eq. metoclopramide 4,457 mg/ml - solution for injection - 5 mg/ml - metoclopramide hydrochloride 5 mg/ml - metoclopramide - dog; cat

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - metoclopramide hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium hydroxide; hydrochloric acid; water for injections; nitrogen; sodium chloride - adults (20 years or older): - relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia. - control of post-operative vomiting - assist in small bowel intubation.,metoclopramide is of little benefit for the prevention or treatment of motion sickness.,young adults and children (over 1 year of age): metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects - severe intractable vomiting of known cause - vomiting associated with radiation therapy or intolerance to cytotoxic drugs. - assist in small bowel intubation

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg in 2 ml - metoclopramide injection (metoclopramide hydrochloride, usp) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. metoclopramide injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. metoclopramide injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g. in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforati

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide  tablets, usp is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux:  metoclopramide tablets, usp are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic g

Malta - English - Medicines Authority

mercury pharma international limited 4045 kingswood road, city west business park, co, dublin, ireland - metoclopramide hydrochloride - solution for injection - metoclopramide hydrochloride 5 mg/ml - drugs for functional gastrointestinal disorders